@RobClarkeLab @ismenasg @DrRachelEyre @DrDAlferez @asimslab @BreastCancerNow @ManchesterBRC @TheChristie Congratulations Rob! This is really exciting as we @TracyRobsonMCT showed that our #FKBPL peptides target STAT3 signalling in #OvarianCancer https://t.
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer #stemcells and #breastcancer #metastasis by downregulating DLL4 and Notch4 https://t.co/2yu3XQ66Cx
New from #The_MRC https://t.co/Hu6MdpTVRV FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
RT @McClementsLana: Important new effects and mechanism of this novel anti-cancer agent targeting angiogenesis and stem cells currently in…
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
RT @BMC_series: Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activi…
Great to see our latest paper is the the editors pick
Editor's Pick #BMCCancer: Robson and her colleagues @MCT_RSCI @UTS_Science present, for the first time, pre-clinical activity of novel systemic anti-cancer therapeutic peptides: https://t.co/OBgRXU89rw. @McClementsLana @steph_annett @drrobclarke @RCSI_Irl
RT @McClementsLana: Important new effects and mechanism of this novel anti-cancer agent targeting angiogenesis and stem cells currently in…
RT @McClementsLana: Important new effects and mechanism of this novel anti-cancer agent targeting angiogenesis and stem cells currently in…
Congratulations @steph_annett ! 🥳
RT @steph_annett: Delighted our new paper is now online "FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer ste…
Congratulations @TracyRobsonMCT and team, great to see my wife’s name as well
Well done @McClementsLana and @steph_annett for all your hard work. @MCT_RCSI @RCSI_Irl @RCSI_Research
Congrats Stephanie.
Delighted our new paper is now online "FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4" @MCT_RCSI @TracyRobsonMCT @McClementsLana https://t.co/XdcVNPaq
RT @McClementsLana: Important new effects and mechanism of this novel anti-cancer agent targeting angiogenesis and stem cells currently in…
With a VADER score of -0.9501 this is the least positive sentiment tweeted recently within the greater Belfast area. https://t.co/Zg6vP37NHf
Important new effects and mechanism of this novel anti-cancer agent targeting angiogenesis and stem cells currently in clinical trials @TracyRobsonMCT @steph_annett
Our paper on FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4 is out now in BMC Cancer https://t.co/C85xmAIlSZ @McClementsLana #FKBPL #BMCcancer